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Background: Dietary changes are a major factor in determining cardiovascular risk. n-3 polyunsaturated fatty acids
modulate the risk factors for metabolic syndrome via multiple mechanisms, including the regulation of the lipid
metabolism. We therefore investigated the effect of Odontella aurita, a microalga rich in EPA, which is already used
as a food supplement, on the risk factors for high-fat diet induced metabolic syndrome in rats.
Methods: Male Wistar rats were divided into 4 groups and were fed with a standard diet (control); with the
standard diet supplemented with 3% freeze-dried O. aurita (COA); with a high-fat diet (HF); or with the high-fat diet
supplemented with 3% of freeze-dried O. aurita (HFOA) for 7 weeks. In this study we evaluated the impact of these
different diets on the risk factors for metabolic syndrome, such as hyperlipidemia, platelet aggregation,
thromboxane B2 production, and oxidative stress.
Results: After 7 weeks of treatment, high fat feeding had increased final body weight, glycemia, triacylglycerol, and
total cholesterol levels in plasma and liver compared to the control diet. Collagen-induced platelet aggregation and
basal platelet thromboxane B2 were also higher in the high-fat fed rats than in those in the control group. In the
liver, oxidative stress was greater in the HF group than in the control group. O. aurita intake in HFOA-fed rats
resulted in lower glycemia and lipid levels in the plasma and liver relative than in the HF group. Thus, in the HFOA
group, n-3 polyunsaturated fatty acid levels in the tissues studied (plasma, liver, and platelets) were higher than in
the HF group. Platelet hyper-aggregability tended to decrease in HFOA-fed rats as basal platelet thromboxane B2
production decreased. Finally, O. aurita reduced oxidative stress in the liver, with lower malondialdehyde levels and
increased glutathione peroxidase activity.
Conclusions: O. aurita is a marine diatom rich in EPA as well as in other bioactive molecules, such as pigments.
The synergistic effect of these microalgal compounds, displayed a beneficial effect in reducing the risk factors for
high-fat induced metabolic syndrome: hyperlipidemia, platelet aggregation, and oxidative stress.
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Metabolic syndrome (MS) has usually been defined on
the basis of a combination of risk factors for cardiovas-
cular diseases (CVDs), such as impaired glucose meta-
bolism, insulin resistance, atherogenic dyslipidemia,
hypertension, and obesity [1]. Lifestyle modifications, in-
cluding abundant calorie-rich food and physical inacti-
vity are recent phenomena in human evolution and may
be responsible for the onset of one or several risk factors
for MS. Several studies have shown that animals fed high
fat and/or high sucrose diets are more likely to develop
risk factors for MS, such as dyslipidemia and hypergly-
cemia [2,3], insulin resistance [4], hepatic steatosis [5,6],
platelet aggregation [7] and oxidative stress [8,9]. While
the prevalence of MS is increasing worldwide [10], stu-
dies have shown that recent dietary modifications such
as low fat diets, high-fiber diets, Mediterranean diets
and diets rich in flavonoids and phenolic acids can re-
duce MS risk factors [11,12]. Another way to reduce risk
in patients with MS may be to increase the relative
abundance of omega-3 (n-3) polyunsaturated fatty acids
(PUFAs) in the diet [13].
The relationship between dietary n-3 PUFA and the
risk of developing cardiovascular diseases is described
in epidemiological, clinical, and animal studies [14-16].
Eicosapentaenoic acid (EPA; 20:5n-3) and docosahexae-
noic acid (DHA; 22:6n-3) are commonly referred to as
bioactive n-3 fatty acids. They are known to reduce
key risk factors for coronary diseases, for instance by
reducing plasma triacylglycerol, arterial and venous
thrombosis, diabetes mellitus, hypertension, and in-
flammation [15]. EPA and DHA also play a key role in
normalizing platelet hyper-aggregability. When added
to the diet, EPA and DHA can alter the phospholipid
membrane composition of the cells, and therefore im-
pact on the synthesis and action of eicosanoids, and
regulate transcription factor activity and abundance.
Another aspect of the action of n-3 fatty acids is to
act as an important mediator of gene expression work-
ing via the peroxisome proliferator-activated receptors
(PPARs) that control the expression of the genes
involved in the lipid and glucose metabolism and adi-
pogenesis [17]. Ethyl-EPA markedly reduced the fatty
droplets in the liver cells of mice fed a high-fat diet,
also lowering plasma levels of total cholesterol and
triacylglycerols [18]. Kajikawa et al. [5] showed that
oral administration of highly purified EPA ethyl ester
(EPA-E) improved hepatic fat accumulation in high
fat/high sucrose diet-fed mice by suppressing the tri-
glyceride (TG) synthesis enzymes regulated by sterol
regulatory element binding protein-1 (SREBP-1) and
decreased the accumulation of hepatic monounsatu-
rated fatty acids (MUFAs) produced by stearoyl-CoA
desaturase 1 (SCD1). Adan et al. [7] showed that EPAand DHA feeding reduces serum cholesterol and tria-
cylcerol levels, and decreases platelet aggregation in
hypercholesterolemic rats.
The richest dietary source of EPA and DHA is fish oils.
However, fish do not synthesize these fatty acids de novo,
as they lack the required key enzymatic activities [19].
Instead, fish accumulate EPA and DHA primarily by
consuming plankton and algae from the marine food
chain [20]. Unfortunately fish also accumulate pollu-
tants, the oil extracted from them also has unpleasant
odor, and the proportion of specific fatty acids in lipids
from this source are difficult to control. These draw-
backs mean that an alternative and renewable source
must be found.
Marine microalgae are the primary producers of n-3
PUFA in the marine food chain. So far, only a few spe-
cies of algae have been approved for use as food comple-
ments, the one most studied is Chlorella sp., a fresh
water unicellular green algae. It contains essential
amino-acids, minerals, fibers, and lipid soluble vitamins
[21,22]. Numerous studies have revealed the biochem-
ical activities of Chlorella, especially when adminis-
tered in the context of underlying disorders, such as
streptozotocin-induced diabetes in rats [23]. Thus, in
rabbits fed a high-cholesterol diet for 10 weeks, Chlo-
rella vulgaris, demonstrated antilipidemic and anti-
atherosclerotic actions [24]. Cherng et al. [2] also
showed that Chlorella pyrenoidosa has the ability to
prevent dyslipidemia in rats and hamsters models fed a
high-fat diet containing 20% hydrogenated coconut oil
(as the source of saturated fatty acids). In a human
study, Lee et al. [25] showed that in male Korean smo-
kers, Chlorella vulgaris supplementation conserved
plasma antioxidant nutrient status and improved
erythrocyte antioxidant enzyme activities. Chlorella in-
take can also lower cholesterol levels in patients with
hypercholesterolemia [26]. These potential health ben-
efits of Chlorella have been attributed to the effects of
specific ingredients in this microalga such as minerals,
dietary fiber, proteins, and n-3 PUFA (18:3n-3). Odontella
aurita is a microalgal marine diatom that is known to
contain high levels of EPA (26% of total fatty acid) and
several bioactive compounds, such as pigments, fibers and
phytosterols, which have beneficial effects on human
health [27,28]. O. aurita is currently approved for use as a
dietary supplement. The studies of Moreau et al. [27]
focus on carotenoids extracted from this microalgae, and
show that an antiproliferative effect was produced in cul-
tures of bronchopulmonary and epithelial cells when
extracts were added to the cell medium. However, no nu-
tritional studies have been yet conducted to demonstrate
the biological effect of O. aurita as a food supplement or
to investigate the possible synergistic effect of various
microalgal compounds.
Table 1 Diet composition
Composition (g/kg) C COA HF HFOA
Casein 230 230 230 230
Corn starch 200 200 130 130
Glucose 380 380 250 250
Cellulose 60 60 60 60
Lard 30 30 230 230
Corn oil 10 10 10 10
Rape oil 10 10 10 10
Mineral 205B SAFE 70 70 70 70
Vitamin 200 SAFE 10 10 10 10
freeze-dried O. aurita - 30 - 30
Analysis was provided by SAFE (Scientific Animal Food & Engineering, Augy,
France).
The mineral mixture provides the following amounts in mg/kg of diet:
CaHPO4, 17.2; KCl, 4000; NaCl, 4000; MgO, 420; MgSO4, 2000; Fe2O3, 120;
FeSO4, 7 H2O, 200; trace elements, 400. Trace element mixture (mg/kg of diet):
MnSO4, H2O, 98; CuSO4, 5 H2O, 20; ZnSO4, H2O, 80; CoSO4, 7 H2O, 0.1; KI, 0.3.
The vitamin mixture provides the following amounts per kg of diet: retinol,
39.600 IU; cholecalciferol, 5000 IU; thiamin, 40 mg; riboflavin, 30 mg;
pantothenic acid, 140 mg; pyridoxine, 20 mg; inositol, 300 mg;
cyanocobolamin, 0.1 mg; ascorbic acid, 1600 mg; choline, 2.720 mg; folic acid,
10 mg; p-aminobenzoic acid, 100 mg; biotin, 0.6 mg.
C, control; COA, control + O. aurita; HF, high fat; HFOA, high fat + O. aurita.
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investigate the effects of freeze-dried O. aurita as a food
supplement on risk factors for high-fat induced MS in
rats fed with a high-fat diet, principally hyperlipidemia
in the bloodstream and liver, platelet aggregation and
oxidative stress, in order to prevent cardiovascular
diseases.
Materials and methods
Animal experiments and diet
Male Wistar rats weighing (120 ± 10 g) were purchased
from (Janvier, CERJ, Le Genest Saint Isle, France) and
housed in pairs in cages with a 12h light/dark cycle and
maintained at 20 ± 2°C. Rats were fed an R-112 standard
diet (SAFE, Augy, France) containing (on a per weight
basis; 5% fat, 23% protein, 58% carbohydrates, 6% cellu-
lose, 7% mineral, and 1% vitamins). After a 1-week accli-
mation period, the rats were randomly assigned to 4
groups, with 6 rats in each. The control group (C), con-
tinued to receive the standard diet (R-112). The second
group (COA) was fed the standard diet supplemented
with 3% (w/w) freeze-dried O. aurita (Innovalg, Bouin,
France). The freeze dried O. aurita content in n-3 PUFA
and pigments was as following: n-3 PUFA (in % of total
fatty acids), total = 32%, EPA = 26%; pigments, total = 9
mg/g of dry matter, chlorophyll a = 30%, fucoxanthin =
20% of total pigments (results provided by Innovalg,
Bouin, France). The third (HF) group received a high fat
diet containing (on a per weight basis: 25% fat, 23% pro-
teins, 38% carbohydrates, 6% cellulose, 7% mineral, and
1% vitamins). The fourth group (HFOA) was fed with
high fat diet supplemented with 3% (w/w) of freeze-
dried O. aurita. The composition of the four diets is
shown in Table 1, and the fatty acid composition of the
different diets is presented in Table 2. The rats had free
access to food and water throughout the study. The
bodyweight gain of the rats was monitored at regular
intervals, and their daily food intake was estimated. All
the experiments involving animals had been approved by
the institutional ethics committee (Direction des Ser-
vices Vétérinaires de la Mayenne, France, N° B53500).
Rats were fed the test diets for 7 weeks and were anaes-
thetized (with Diazepam/Ketamine 4v/3v), following an
overnight fast on day 49, and exsanguinated via the ab-
dominal aorta. The liver and adipose tissue were
removed, rinsed with ice-cold saline solution (0.9%
NaCl) and stored at (-70°C).
Platelet aggregation assay
Platelet preparation
Blood was recovered in polyethylene tube containing
Acid-Citric-Dextrose anticoagulant (9:1 v/v) (citric acid
130 mM, trisodium citrate 170 mM, dextrose 4%).
Washed platelets were prepared as described previouslyby Mekhfi et al. [29] with some modifications. Briefly,
blood was centrifuged at 230 × g for 15 min to obtain
platelet rich plasma (PRP). The supernatant (PRP) was
then centrifuged at 120 × g for 8 min to remove any re-
sidual erythrocytes and leukocytes. The platelet rich
plasma obtained was acidified to pH 6.5 with citric acid
0.15 M to inhibit spontaneous aggregation. PRP was
then centrifuged at 900 × g for 15 min to obtain platelet
pellets. The cells were finally suspended in Tyrode buffer
(NaCl 137 mM, KCl 2.6 mM, MgCl2 0.9 mM, glucose
5.5 mM, gelatin 0.25%, HEPES 5 mM, CaCl2 1.3 mM pH
7.4). Platelet poor plasma (PPP) was recovered for lipid
analysis.
Platelet aggregation
Platelet aggregation was measured turbidimetrically in
washed platelet suspensions [30] using an APACT 4004,
4-channel platelet aggregometer (LABiTEC, Ahrensburg,
Germany). Platelet suspension concentrations were esti-
mated by a Coulter cell counter (Beckman Coulter, Ville-
pinte, France), and the concentrations were adjusted to
5×108 cells/mL using Tyrode buffer. Aggregation tests
were performed at 37°C in cuvettes stirred at 1000 rpm.
Washed platelets (225 μL) were stimulated with ADP 10
μM (Sigma-Aldrich, Saint-Quentin Fallavier, France) or
with Collagen (Kordia, Lille, France) 5 μg/mL. The light
transmission was recorded for 5 min after platelet stimu-
lation. The platelet aggregation was quantified as the
maximum change in light transmission through a
washed platelet solution expressed as a percentage of
the light transmission through the blank (Tyrode buffer).
Table 2 Dietary fatty acid composition
Fatty acids
(% molar)
C COA HF HFOA
14:0 0.94 ± 0.12 1.00 ± 0.15 1.50 ± 0.14 1.67 ± 0.19
16:0 17.16 ± 1.70 17.72 ± 1.86 24.58 ± 1.03 25.49 ± 1.53
16:1n-7 1.39 ± 0.05 2.41 ± 0.14 0.23 ± 0.06 0.23 ± 0.04
18:0 9.19 ± 0.16 8.53 ± 0.23 11.53 ± 0.31 11.29 ± 0.30
18:1n-7+n-9 45.02 ± 2.54 42.31 ± 2.81 42.69 ± 1,96 42.06 ± 2.12
18:2n-6 20.14 ± 1.81 18.86 ± 1.54 12.33 ± 0.47 11.92 ± 0.51
18:4n-3 0.4 ± 0.02 0.37 ± 0.03 0.22 ± 0.01 0.21 ± 0.01
20:4n-6 - - 0.16 ± 0.02 0.15 ± 0.02
20:5n-3 - 0.83 ± 0.16 - 0.76 ± 0.11
22:6n-3 - tr - tr
Total lipids were extracted from diets according to Folch et al. method [31].
Fatty acid methyl ester (FAMEs) were prepared according to the method of
Slover and Lanza [33] and analyzed by gas chromatography as described in
material and methods section. Values are expressed as mean ± SD (n=3). C,
control; COA, control + O. aurita; HF, high fat; HFOA, high fat + O. aurita. tr:
traces.
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Total lipids were extracted from the liver with chloroform/
methanol (2:1 v/v) according to the method of Folch
et al. [31]. Furthermore total lipids were extracted from
the platelets and plasma using the Bligh and Dyer
method [32]. Phospholipids (PLs) and neutral lipids
(NLs) were separated from the total lipids by solid phase
extraction using silica gel columns Sep-pak (Sep-Pak
plus, silica cartridges, Waters, France). Fatty acid methyl
esters (FAMEs) were prepared according to the method
of Slover and Lanza [33], and analyzed with a FOCUS
gas-chromatography instrument (Thermo Electron Cor-
poration, Les Ulis, France) equipped with a capillary
column CP Sil-88 25 m × 0.25 mm id (Varian, Les Ulis,
France). Analyses were carried out from 150°C to 220°C.
The esters were detected with a flame-ionization de-
tector. Individual fatty acids were identified from au-
thentic fatty acid methyl ester standards (Sigma-
Aldrich, Saint-Quentin Fallavier, France), and expressed
as a percentage of total fatty acids.
Biochemical analysis
Glycemia was measured in rat tails using a glucometer
(FreeStyle PAPILLON mini, Abbott, Rungis, France).
However, plasma triacylglycerol and total cholesterol
levels were determined by enzymatic methods, using com-
mercial Kits (Biomérieux S.A, Marcy l’Etoile, France).
Triacylglycerol and total cholesterol levels were also
determined in the liver using total lipids extracted by
enzymatic methods.
Measurement of lipid peroxidation in platelets and liver
Lipid peroxidation was evaluated by measuring the level
of malondialdehyde (MDA) by the Ohkawa method [34].
0.5 g of liver was homogenized with 4.5 mL KCl solution(1.15%). To 0.5 mL washed platelet solution or 0.1 mL
liver homogenate was added 0.1 mL 8.1% sodium dode-
cyl sulfate (SDS), 0.75 mL acetic acid 20% pH 3.5, 0.75
mL thiobarbituric acid (TBA) 0.8% and distilled water to
make the volume up to 2.5 mL. The tubes were placed
in a water bath at 95°C for 60 min, and then imme-
diately cooled in ice. 0.5 mL of water and 2.5 mL of a so-
lution of n-butanol and pyridine (15:1 v/v) were added
to each tube, which was then shaken vigorously and then
centrifuged at 1000 × g for 10 min. The organic phase
corresponding to the upper layer was aspired and the
color intensity was measured at 532 nm. The standard
range was prepared using the1,3,3,3- tetramethoxypro-
pane (Sigma-Aldrich, Saint-Quentin Fallavier, France)
solution.Glutathione peroxidase assay
The platelet content was released by sonication. The lysate
was centrifuged at 4000 × g for 10 min and the super-
natant was used to determine the platelet glutathione per-
oxidase activity. The liver was homogenized in KCl
solution (1.15%) using a Potter tissue homogenizer then
centrifuged at 4000 × g for 10 min. Liver glutathione per-
oxidase activity was measured in the supernatant.
The glutathione peroxidase (GPx) activity was deter-
mined according to Paglia and Valentine method [35] as
modified by Chaudiére and Gérard [36]. Briefly, to a
final volume of 1.5 mL containing Tris-HCl/EDTA (50
mM/0.1 mM) pH 7.6, NADPH,H+ (0.14 mM), reduced
glutathione (GSH) (2 mM) and 0.7 U/mL of GSSG-re-
ductase, was added 100 μL of platelet lysate or 100 μL of
liver homogenate. The mixture was incubated at 37°C
for 3 min. The reaction was started by adding 50 μL ter-
tiary butyl hydroperoxide (t-BH) (0.2 mM). The change
in absorbance was recorded at 340 nm for 5 min at 5 s
intervals. An appropriate control without samples was
run simultaneously. GPx activity was expressed in
nmoles of hydroperoxide reduced per min and per mg
protein.Protein assay
Protein was determined by Bradford’s colorimetric
method [37] using Biorad reagent, with bovine serum al-
bumin (Sigma-Aldrich, Saint-Quentin Fallavier, France)
as standard.Thromboxane B2 measurement
Rat washed platelets underwent three successive freeze/
thaw cycles to release the cell content. The basal TXB2
level was measured using an enzyme immunoassay
(EIA) Kit (Enzo-Life sciences, Exeter, UK) according to
the manufacturer’s recommendations.
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All values were expressed as the mean ± SD. After ana-
lysis of variance, the mean values were compared using
Fisher's least significant difference test (Statgraphics Plus
5.1, Manugistics Inc., Rockville, MD, USA).
Results
Effect of diet treatments on body and organ weights
As shown in Table 3, the final bodyweight of the rats on
the high-fat (HF) diet was significantly higher than that
of the control (C) diet rats. Feeding with either the con-
trol or high-fat diet supplemented with O. aurita (COA
and HFOA respectively) tended to decrease the final
body weight after 7 weeks of diet treatment compared to
both C and HF feeding, but this effect failed to reach
statistical significance. With regard to organ weights
(Table 3), only the adipose tissue was affected by the
dietary treatments. The data showed that the HF diet
significantly increased adipose tissue weight (p < 0.016)
compared to the C diet. Adipose tissue weight/final body
weight ratio (AT/Bw) was also calculated to evaluate the
development of adiposity. The AT/Bw ratio was signifi-
cantly greater in HF-fed rats than in the controls. The
increased adiposity was prevented by O. aurita intake in
the HFOA group, where the adipose tissue weight was
reduced, and the AT/Bw ratio lower than that in HF-fed
rats. Daily food intake was significantly greater in the C
and COA groups than in the HF and HFOA groups.
However, the daily energy intake did not differ for the
different dietary treatments.
Effect of diet treatments on plasma and liver lipid levels
The in-vivo hypolipidemic and hypoglycemic effects of
O. aurita intake was evaluated (Table 4). The HF group
registered a significant increase in plasma glucose, triacyl-
glycerols (TG) and total cholesterol compared to the C
group (p < 0.009, p = 0.001 and p = 0.035 respectively).
The presence of O. aurita produced a hypoglycemic and
hypolipidemic effect in the HFOA-fed rats compared to
the HF group. In the liver, the data revealed that liver
lipids, especially TG and total cholesterol, wereTable 3 Animal characteristics after 7 weeks of treatment
Diet groups C COA
Organs (g)
Body weight (Bw) 359.1 ± 18.7bc 339.1 ± 27.8c
Liver weight (Lw) 11.1 ± 1.5 10 ± 0.7
Adipose tissue (AT) 4.5 ± 1.6b 4.8 ± 1.1b
AT/Bw (%) 1.2 ± 0.5b 1.4 ± 0.3ab
Daily food intake (g/day) 46.2 ± 12.8a 42.8 ± 9.2a
Energy intake (Kcal/day) 170.47 ± 47.23 161.3 ± 34.7
Results are expressed as mean ± SD (n=5). After a one-way ANOVA, Student–Newm
order from left to right: a > b > c (p < 0.05). C, control; COA, control + O. aurita; HFsignificantly greater in the HF group than in the controls
(p < 0.001). The liver TG and total cholesterol levels were
significantly lower in the HFOA-fed rats than in the HF
group (Table 4).
Effect of diet treatments on plasma total lipid fatty acid
composition
The plasma total lipid fatty acid composition in each
group of rats is reported in Table 5. After 7 weeks of
treatment, the data revealed a significant change in the
plasma total lipid fatty acid composition with the differ-
ent dietary treatments. O. aurita intake in the COA and
HFOA-fed rats significantly (p = 0.024) increased their
total n-3 level compared to the C and HF groups, re-
spectively. The increased n-3 level was mainly related to
the EPA (20:5 n-3) rate, the main polyunsaturated fatty
acid (PUFA) in microalgae. Furthermore, the data
revealed that the DHA (22:6 n-3) level was significantly
greater in the COA and HFOA groups than in the C
and HF groups respectively (p = 0.042). Total n-3
increase with O. aurita intake induced a decrease of the
n-6/n-3 PUFA ratio in the plasma in HFOA-fed rats
compared to the HF group.
Effect of diet treatments on platelet aggregation, TxB2
production, and platelet phospholipid composition
The effect of dietary treatment on ADP and collagen-
induced platelet aggregation is reported in Figure 1. The
maximum aggregation percentage is presented in Table 6.
The data did not reveal any difference in ADP-induced
platelet aggregation in the different groups. However, O.
aurita intake in HFOA-fed rats tended to normalize the
platelet aggregation induced by collagen compared to
the HF-fed rats (p = 0.05), but this effect failed to reach
statistical significance.
The effects of O. aurita supplementation of a high fat
diet on the basal platelet level of thromboxane B2 is
shown in Figure 2. The basal levels of eicosanoids in pla-
telets are influenced by dietary fat. Rats fed with the HF
diet displayed a significantly higher amount of TXB2 in
the platelet suspension than those fed with the controlHF HFOA p value
389.1 ± 13.1a 378.7 ± 27.4ab 0.008
10.6 ± 0.6 11 ± 0.9 N.S
6.9 ± 0.8a 4.3 ± 0.9b 0.016
1.8 ± 0.3a 1.1 ± 0.2b 0.045
35.9 ± 8.7b 32.3 ± 8.8b < 0.001
168.23 ± 40.8 154.07 ± 41.97 N.S
an–Keuls (SNK) multiple comparison test, results are arranged in increasing
, high fat; HFOA, high fat + O. aurita. N.S: Not significant.
Table 4 Glycemia and plasma and liver lipids determinations after 7 weeks of treatment
Diet groups C COA HF HFOA p value
Plasma (mmol/L)
Glucose 4.30 ± 0.49b 3.96 ± 0.27b 5.17 ± 0.74a 4.57 ± 0.51ab 0.009
Triacylglycerols 0.84 ± 0.07b 0.90 ± 0.06b 1.06 ± 0.04a 0.91 ± 0.09b 0.001
Total cholesterol 1.49 ± 0.22b 1.57 ± 0.22b 1.87 ± 0.17a 1.51 ± 0.13b 0.035
Liver (mg/g)
Triacylglycerols 12.04 ± 2.48bc 10.14 ± 1.00c 28.28 ± 4.97a 16.62 ± 4.15b < 0.001
Total cholesterol 2.97 ± 0.49b 2.64 ± 0.35b 4.19 ± 0.66a 2.88 ± 0.17b < 0.001
Results are expressed as mean ± SD (n=5). After a one-way ANOVA, Student–Newman–Keuls (SNK) multiple comparison test, results are arranged in increasing
order from left to right: a > b > c (p < 0.05). C, control; COA, control + O. aurita; HF, high fat; HFOA, high fat + O. aurita.
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HFOA diet was 16.6% lower than in the HF-fed rats,
which was a significant difference.
The fatty acid composition of platelet phospholipids
showed that O. aurita intake increased the total n-3
PUFA level when added to the HF diet (Table 7).
Increased n-3 in HFOA fed rats involved docosapentae-
noic acid (DPA), which represents an EPA conversion
product. The total n-6/n-3 ratios were also lower in the
HFOA group than in HF-fed rats.
In platelets, the redox status is a critical modulator of
platelet function. Figure 3 presents the MDA level and
GPx activity in platelets. The data show that HF feeding
tended to increase the level of MDA and decrease GPx
activity in rat platelets. O. aurita showed a tendency toTable 5 Plasma total lipid fatty acid composition of rats after
Diet groups C COA
Fatty acids (% molar)
14:0 0.32 ± 0.07ab 0.34 ± 0.10a
16:0 17.84 ± 1.86a 16.94 ± 1.65ab
16:1 1.51 ± 0.27a 1.69 ± 0.28a
18:0 9.41 ± 0.74b 8.76 ± 0.60b
18:1n-7 + n-9 18.60 ± 3.84 16.84 ± 2.85
18:2n-6 10.40 ± 0.87 10.99 ± 1.40
18:3n-3 0.18 ± 0.05 0.25 ± 0.04
20:1n-9 0.27 ± 0.06a 0.34 ± 0.09a
20:4n-6 23.25 ± 3.22 23.44 ± 2.96
20:5n-3 0.27 ± 0.07b 0.60 ± 0.16a
22:5n-3 0.48 ± 0.0.22 0.46 ± 0.06
22:6n-3 4.42 ± 1.19ab 5.31 ± 0.66a
SFA 27.58 ± 1.49 26.10 ± 1.83
MUFA 20.38 ± 4.14 18.87 ± 2.89
Total n-3 5.22 ± 1.1ab 5.99 ± 1.04a
Total n-6 33.64 ± 2.54b 34.44 ± 2.62b
MUFA / SFA 0.73 ± 0.11 0.72 ± 0.10
n-6 / n-3 6.63 ± 1.18b 5.88 ± 1.09b
Results are expressed as mean ± SD (n=5). After a one-way ANOVA, Student–Newm
order from left to right: a > b > c (p < 0.05). C, control; COA, control + O. aurita; HFenhance platelet redox status by reducing the level of
MDA and increasing GPx activity, but this effect failed
to reach statistical significance.
Effect of diet treatments on liver phospholipids and
neutral lipid fraction compositions
The fatty acid compositions of the liver phospholipids
(PL) and neutral lipids (NL) are reported in Tables 8 and
9 respectively. After a 7-week period on the experimen-
tal diets, the data showed that after O. aurita intake by
COA and HFOA-fed rats, EPA incorporation into the
liver phospholipid fraction was significantly greater than
in the C and HF-fed rats, respectively. Thus, DPA and
DHA levels in liver PL, were significantly higher in the
HFOA group than in the HF-fed rats, but there was no7 weeks of treatment
HF HFOA p value
0.20 ± 0.03b 0.23 ± 0.06b 0.025
15.11 ± 0.72bc 14.83 ± 1.46c 0.010
0.56 ± 0.05b 0.58 ± 0.12b < 0.001
12.08 ± 0.85a 11.29 ± 0.69a < 0.001
15.87 ± 1.53 16.09 ± 2.39 N.S
12.09 ± 0.96 10.98 ± 1.00 N.S
0.24 ± 0.05 0.22 ± 0.04 N.S
0.15 ± 0.03b 0.16 ± 0.04b < 0.001
26.64 ± 1.76 23.40 ± 3.48 N.S
0.19 ± 0.05b 0.33 ± 0.09b < 0.001
0.33 ± 0.04 0.43 ± 0.07 N.S
3.64 ± 0.70b 4.92 ± 0.70a 0.042
27.40 ± 0.86 26.35 ± 1.77 N.S
16.57 ± 1.60 16.83 ± 2.51 N.S
4.22 ± 0.68b 5.71 ± 0.67a 0.024
38.74 ± 0.95a 34.39 ± 3.88b 0.035
0.60 ± 0.07 0.64 ± 0.07 N.S
9.35 ± 1.37a 6.12 ± 1.19b < 0.001
an–Keuls (SNK) multiple comparison test, results are arranged in increasing
, high fat; HFOA, high fat + O. aurita. N.S: Not significant.
A B% Aggregation % Aggregation
Time (s) Time (s)
Figure 1 Platelet aggregation measurement after 7 weeks of treatment with different diets. Washed platelets were stimulated with
collagen (5 μg/mL): A or with ADP (10 μM): B. C, control; HF, high fat; HFOA, high fat + O. aurita.
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COA and C groups. Furthermore, the n-6/n-3 PUFA
ratio was significantly lower in the liver PL of HFOA-fed
rats than in that of the HF group animals.
Compared to the liver PL fraction, more modifications
were revealed in the composition of NL (Table 9). Beside
total n-3 enrichment in the liver NL fraction, especially
with EPA, DPA, and DHA, the data showed that the
total monounsaturated fatty acid (MUFA) level, espe-
cially of 16:1n-7 and 18:1n7 + 18:1n-9 MUFA levels, was
significantly higher in the COA and HFOA groups than
in the C and HF groups. The n-6/n-3 PUFA ratio was
also lower in the liver NL fraction in COA and HFOA-
fed rats than in the C and HF groups.
Effect of diet treatments on the level of MDA and on GPx
activity in liver
The hepatic MDA level and GPx activity are shown in
Figure 4. A significantly higher liver MDA level was
observed in the HF group than in the C group. O. aurita
intake in HFOA-fed rats resulted in a significantly lower
MDA level in the liver than in HF-fed rats. Thus, after 7
weeks of treatment, the HF diet had induced a signifi-
cantly lower level of hepatic GPx activity than the C diet.
However, HF diet supplementation with O. auritaTable 6 Effect of dietary regimens on rat platelet
aggregation after 7 weeks of treatment
% maximum aggregation
C HF HFOA p value
Collagen 5 μg/mL 68.35 ± 3.56b 80.29 ± 3.59a 72.42 ± 1.09ab 0.053
ADP 10 μM 80.18 ± 5.72 87.63 ± 5.09 86.97 ± 4.44 N.S
Values are means ± SD of 4 independent determinations (animals). After a
one-way ANOVA, Student–Newman–Keuls (SNK) multiple comparison test
results are arranged in increasing order from left to right: a > b > c (p < 0.05).
C, control; HF, high fat; HFOA, high fat + O. aurita. N.S: Not significant.resulted in significantly greater antioxidant activity of
GPx in the liver than that observed with the HF diet.
Discussion
The present investigation was undertaken to assess the
influence of O. aurita, a marine diatom rich in EPA, on
the risk factors for high-fat induced MS in rats. In this
study, the HF diet group rats had significantly higher
final body weight, adiposity, blood glucose, TG and total
cholesterol levels than were found in the animals in the
C group. Abdominal obesity and insulin resistance have
been proposed as being the main causal factors of MS
[38]. It was also found that O. aurita intake in HFOA
group decreased adipose tissue weight, plasma glucose,
and TG and total cholesterol levels, but had no effect on
final body weight in the COA or HFOA groups as com-
pared to the C and HF groups respectively. These results
suggest that the administration of O. aurita reduces MS
risk factors by lowering glycemia and blood lipid levels.
Marine organisms such as fish and microalgae are
known to be rich in n-3 fatty acids, and specifically in
EPA and DHA. Previous studies have already reported
that purified EPA or DHA have differing effects on para-
meters involved in cardiovascular disease prevention
[15]. Matzusawa et al. [38] showed that n-3 PUFA plays
an important role in preventing obesity by acting on the
adipocytokines that regulates lipid and glucose homeo-
stasis. Itoh et al. [39] reported that dietary EPA increased
adiponectin secretion in genetically and high-fat diet
induced obese mice. Indeed, the consumption of fish oil
enriched in EPA can markedly reduce the levels of
plasma triacylglycerols and associated very-low-density
lipoprotein (VLDL) in the circulation in healthy subjects
and selected patients with hypertriglyceridemia [40].
Nemoto et al. [18] showed that EPA markedly reduced




























Figure 2 Effect of O. aurita supplementation to high fat diet on
the basal platelets thromboxane B2 level. Values are expressed
as the mean ± SD (n = 5). Values bearing different superscript letters
are significantly different from each other. (P = 0.009) After a one-
way ANOVA, Student–Newman–Keuls (SNK) multiple comparison
test, results are arranged in increasing order from left to right: a > b
> c (p < 0.05). C, control; HF, high fat; HFOA, high fat + O. aurita.
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high fat-fed mice.
Platelet aggregation is considered to be closely
involved in the development of arterial thrombosis after
the formation of atherosclerotic plaques [41]. Further-
more, a variety of platelet functions abnormalities, in-
cluding increased adhesiveness and activation in vitroTable 7 Platelet phospholipids fatty acid composition of
rats after 7 weeks of treatment
Diet groups C HF HFOA p value
Fatty acids (% molar)
14:0 0.44 ± 0.04 0.53 ± 0.10 0.59 ± 0.06 N.S
16:0 24.54 ± 0.55 24.93 ± 0.28 25.72 ± 0.68 N.S
16:1 0.50 ± 0.05a 0.26 ± 0.02b 0.25 ± 0.00b < 0.001
18:0 13.90 ± 0.29 14.49 ± 0.12 14.25 ± 0.99 N.S
18:1n-7 + n-9 8.82 ± 0.20a 7.71 ± 0.28b 7.06 ± 0.33c < 0.001
18:2n-6 4.33 ± 0.04 4.66 ± 0.39 4.39 ± 0.10 N.S
18:3n-3 0.49 ± 0.02 0.57 ± 0.03 0.54 ± 0.05 N.S
20:1n-9 0.46 ± 0.01 0,57 ± 0.06 0.54 ± 0.06 N.S
20:4n-6 25.88 ± 0.33a 23.80 ± 0.52b 23.80 ± 0.65b 0.004
20:5n-3 0.20 ± 0.03 0.17 ± 0.03 0.22 ± 0.00 N.S
22:5n-3 0.36 ± 0.06b 0.39 ± 0.05b 0.52 ± 0.03a 0.018
22:6n-3 0.47 ± 0.08 0.48 ± 0.05 0.63 ± 0.14 N.S
SFA 38.89 ± 0.45b 39.95 ± 0.22a 40.57 ± 0.38a 0.004
MUFA 9.78 ± 0.21a 8.55 ± 0.25b 7.85 ± 0.28c < 0.001
Total n-3 1.52 ± 0.19b 1.63 ± 0.05b 1.92 ± 0.12a 0.029
Total n-6 30.21 ± 0.36a 28.47 ± 0.54b 28.19 ± 0.71b 0.009
MUFA / SFA 0.25 ± 0.00a 0.21 ± 0.00b 0.19 ± 0.00c < 0.001
n-6 / n-3 20.02 ± 2.75a 17.48 ± 0.86b 14.71 ± 0.71bc 0.025
Results are expressed as mean ± SD (n=6). After a one-way ANOVA,
Student–Newman–Keuls (SNK) multiple comparison test, results are arranged
in increasing order from left to right: a > b > c (p < 0.05). C, control; HF, high
fat; HFOA, high fat + O. aurita. N.S: Not significant.and in vivo and increased sensitivity to physiological
agonists, have been identified in obese subjects [42]. The
polyunsaturated fatty acids EPA and DHA play a crucial
role in reducing platelet aggregation [43]. In the present
investigation we compared platelet activities in three
groups: control, C, high-fat, HF, and high fat + O. aurita,
HFOA. It was found that rats fed the HFOA diet dis-
played lower collagen-induced platelet aggregation, but
not in ADP-induced platelet aggregation, than rats fed
with the HF diet. The decrease in platelet aggregation in
the HFOA group was confirmed by the lower TXB2 level
in this group compared to the HF group. The fatty acid
composition of platelet phospholipids revealed higher
levels of n-3 PUFA in the HFOA than in the HF group.
These findings could be explained by the incorporation
and conversion of EPA produced by the microalgae in
the platelet phospholipids. When n-3 PUFA are con-
sumed they are selectively incorporated into the phos-
pholipids of the platelet membrane, and thus decrease
the release and formation of TXB2, which is a potent in-
ducer of platelet aggregation. Burri et al. [44] have
shown that the consumption of a diet high in linoleic
acid (LA) decreases ADP- and collagen-induced platelet
aggregation compared to a diet containing oleic acid.
Studies by Kwon et al. [45] have found that the con-
sumption of both oleic acid and linoleic acid reduce
collagen-induced platelet aggregation compared to that
found in subjects consuming a diet high in saturated
fatty acids. Moreover, Véricel et al. [46] showed that a
small intake of n-3 PUFA reduced the oxidative stress in
the platelets of elderly people, and could be beneficial to
subjects with atherothrombotic tendencies by lowering
the cell peroxide tone.
The levels of n-3 fatty acids incorporated into tissue
lipids can be considered to be a cardiovascular disease
risk marker, as has often been reported previously
[47,48]. The results reported in Tables 5, 7, 8 and 9
showed higher levels of n-3 PUFA in the plasma and
liver fatty acid compositions in rats fed with COA and
HFOA diets than those in rats on the fed with C or HF
diets. These results show that the EPA provided by the
O. aurita diet is incorporated into the plasma and liver
lipids. Moreover, there is a relationship between food in-
take and lipid enrichment with EPA. The rats fed the
COA diet had a higher food intake than those receiving
the HFOA diet, and higher EPA levels were observed in
the plasma and liver in the COA group than in the
HFOA group.
The liver is a very important site for maintaining body
lipid homeostasis. Our data show that rats fed with the
HF diet had higher hepatic TG and total cholesterol
levels than HFOA-fed rats, which suggests that O. aurita
could regulate hepatic genes involved in lipid metabo-
lism through the effect of EPA. Stearoyl-CoA desaturase

























































Figure 3 Effect of O. aurita supplementation to high fat diet on platelets oxidative stress after 7 weeks of treatment. (A): effect of
O. aurita on platelets MDA level (p = 0.180); (B): effect of O. aurita on platelets GPx activity (p = 0.617). Values are expressed as the mean ± SD
(n = 5). After a one-way ANOVA, Student–Newman–Keuls (SNK) multiple comparison test, results are arranged in increasing order from left to
right: a > b > c (p < 0.05). C, control; HF, high fat; HFOA, high fat + O. aurita.
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http://www.lipidworld.com/content/11/1/147(SCD) is an endoplasmic reticulum enzyme that cata-
lyzes the biosynthesis of monounsaturated fatty acids
(MUFAs) from saturated fatty acids (SFAs) that are ei-
ther synthesized de novo or derived from the diet. The
regulation of this process plays a critical role in disorders
such as obesity, diabetes, and atherosclerosis. SCD1, the
main SCD isoform expressed in liver, is a key player in
the regulation of lipid partitioning in liver. The import-
ance of SCD1 in neutral lipid synthesis in liver has beenTable 8 Phospholipid fatty acid composition in liver rat after
Diet groups C COA
Fatty acids (% molar)
14:0 0.31 ± 0.18 0.18 ± 0.04
16:0 17.86 ± 1.69a 17.15 ± 0.90a
16:1 0.20 ± 0.07 0.16 ± 0.06
18:0 21.82 ± 2.05b 21.99 ± 1.11b
18:1n-7 + n-9 9.12 ± 1.05a 8.76 ± 0.51a
18:2n-6 8.80 ± 0.93 9.48 ± 0.96
18:3n-3 0.10 ± 0.03 0.10 ± 0.01
20:1n-9 0.14 ± 0.05 0.13 ± 0.03
20:4n-6 27.80 ± 1.83ab 26.31 ± 1.64b
20:5n-3 0.14 ± 0.04bc 0.28 ± 0.07a
22:5n-3 0.57 ± 0.08b 0.66 ± 0.09ab
22:6n-3 7.79 ± 0.50a 7.80 ± 0.30a
SFA 39.99 ± 0.83b 39.47 ± 0.59b
MUFA 9.65 ± 1.00a 9.04 ± 0.55a
Total n-3 8.47 ± 0.49a 8.81 ± 0.47a
Total n-6 36.60 ± 1.03b 37.57 ± 0.95ab
Δ9 desaturase index 0.29 ± 0.04a 0.29 ± 0.02a
MUFA / SFA 0.25 ± 0.04a 0.23 ± 0.02a
n-6 / n-3 4.32 ± 0.18b 4.15 ± 0.30b
Results are expressed as mean ± SD (n=5). After a one-way ANOVA, Student–Newm
order from left to right: a > b > c (p < 0.05). C, control; COA, control + O. aurita; HF
index = [18:1n-7 + n-9/(18:0 + 18:1n-7 + n-9)].confirmed by studies in SCD1 -/- mice, in which an
SCD1 deficiency leads to a fall in the hepatic triacylgly-
cerol and cholesterol ester contents [49,50] and down
regulates de novo fatty acid synthesis [51]. The results
shown in Table 9 show a lower level of total MUFA in
liver neutral lipids in the HF group than in the controls.
However, the lower MUFA level was enhanced by O.
aurita intake in HFOA fed rats. These results may sug-
gest the potential regulation of SCD1 by O. aurita.7 weeks of diet
HF HFOA p value
0.14 ± 0.03 0.16 ± 0.07 N.S
14.97 ± 0.54b 14.99 ± 1.14b < 0.001
0.15 ± 0.05 0.14 ± 0.03 N.S
26.98 ± 0.39a 26.57 ± 0.69a < 0.001
7.30 ± 0.77b 7.15 ± 0.68b 0.001
9.65 ± 0.61 9.43 ± 0.54 N.S
0.07 ± 0.01 0.09 ± 0.03 N.S
0,12 ± 0.04 0.10 ± 0.03 N.S
29.37 ± 0.60a 28.57 ± 1.62a 0.044
0.12 ± 0.03c 0.20 ± 0.03b < 0.001
0.61 ± 0.06b 0.71 ± 0.09a 0.038
6.94 ± 0.60b 7.46 ± 0.39ab 0.025
42.14 ± 0.67a 41.77 ± 0.67a < 0.001
6.83 ± 0.90b 7.62 ± 0.75b < 0.001
7.68 ± 0.65b 8.35 ± 0.29a 0.009
38.99 ± 0.5a 38.00 ± 1.34ab 0.025
0.20 ± 0.03b 0.21 ± 0.02b 0.002
0.17 ± 0.02b 0.17 ± 0.01b < 0.001
5.13 ± 0.52a 4.55 ± 0.24b 0.002
an–Keuls (SNK) multiple comparison test, results are arranged in increasing
, high fat; HFOA, high fat + O. aurita. N.S: Not significant. Δ9 desaturase
Table 9 Liver neutral lipids fatty acid composition of rats after 7 weeks of treatment
Diet groups C COA HF HFOA p value
Fatty acids (% molar)
14:0 0.95 ± 0.06a 0.88 ± 0.32a 0.51 ± 0.17b 0.64 ± 0.29ab 0.030
16:0 25.53 ± 2.22 24.39 ± 2.73 22.84 ± 0.55 23.07 ± 1.80 N.S
16:1 3.75 ± 1.00a 3.41 ± 0.74a 0.34 ± 0.03b 0.40 ± 0.07b < 0.001
18:0 6.06 ± 1.76 5.75 ± 2.58 5.42 ± 1.32 4.39 ± 0.86 N.S
18:1n-7 + n-9 35.06 ± 4.60b 35.84 ± 3.57b 32.97 ± 1.90b 41.00 ± 2.48a 0.005
18:2n-6 11.41 ± 1.96b 11.20 ± 2.91b 15.14 ± 1.57a 14.61 ± 1.36a 0.008
18:3n-3 0.46 ± 0.20 0.54 ± 0.16 0.62 ± 0.06 0.65 ± 0.10 N.S
20:1n-9 0.14 ± 0.01c 0.40 ± 0.06a 0.15 ± 0.00c 0.28 ± 0.00b < 0.001
20:4n-6 3.89 ± 0.45 3.39 ± 0.81 3.27 ± 0.78 3.64 ± 1.44 N.S
20:5n-3 0.13 ± 0.04b 0.33 ± 0.16a 0.15 ± 0.04b 0.19 ± 0.05b 0.011
22:5n-3 0.16 ± 0.03b 0.35 ± 0.10a 0.12 ± 0.01b 0.41 ± 0.15a < 0.001
22:6n-3 1.09 ± 0.07b 1.58 ± 0.17a 1.02 ± 0.19b 1.14 ± 0.06b 0.004
SFA 32.75 ± 1.26a 31.02 ± 2.41a 28.77 ± 1.65b 28.72 ± 0.9b 0.002
MUFA 38.88 ± 4.19ab 42.15 ± 5.39a 33.60 ± 2.06b 42.97 ± 4.00a 0.007
Total n-3 1.88 ± 0.16b 2.68 ± 0.43a 1.94 ± 0.27b 2.78 ± 0.68a 0.043
Total n-6 14.96 ± 2.01 14.14 ± 2.48 20.40 ± 4.18 19.52 ± 3.55 N.S
Δ9 desaturase index 0.85 ± 0.05 0.86 ± 0.05 0.86 ± 0.03 0.89 ± 0.03 N.S
MUFA / SFA 1.19 ± 0.15b 1.55 ± 0.24a 1.17 ± 0.06b 1.49 ± 0.09a 0.004
n-6 / n-3 7.37 ± 0.94ab 5.56 ± 0.60c 8.44 ± 0.84a 7.25 ± 0.66b 0.001
Results are expressed as mean ± SD (n=5). After a one-way ANOVA, Student–Newman–Keuls (SNK) multiple comparison test, results are arranged in increasing
order from left to right: a > b > c (p < 0.05). C, control; COA, control + O. aurita; HF, high fat; HFOA, high fat + O. aurita. N.S: Not significant. Δ9 desaturase index =
[18:1n-7 + n-9/(18:0 + 18:1n-7 + n-9)].
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http://www.lipidworld.com/content/11/1/147Velliquette et al. [52] showed that diets enriched in
linoleic acid, α-linolenic acid and, by metabolic infe-
rence, EPA, can regulate SCD activity at the level of
transcription.
Numerous studies have shown that oxidative stress is
increased in obesity, which is an essential component of
MS, and that reactive oxygen species (ROS) levels can



































Figure 4 Effect of O. aurita supplementation of standard or high fat d
(A): effect of O. aurita on hepatic MDA level (p = 0.006); (B): effect of O. au
mean ± SD (n = 5). Values bearing different superscript letters are significan
Newman–Keuls (SNK) multiple comparison test, the results are arranged in
COA, control + O. aurita; HF, high fat; HFOA, high fat + O. aurita.induced by a high fat diet leads to enhanced oxidative
stress in rats [54]. Roberts et al. [55] also showed that
ROS were overproduced in a rat model of MS induced
by a diet high in fat and refined sugar. The results shown
in Figure 3 showed that O. aurita intake in HFOA group
resulted in significantly lower hepatic oxidative stress
after 7 weeks of treatment than in HF fed rats. Rats fed



























iets on hepatic oxidative stress after 7 weeks of treatment.
rita on hepatic GPx activity (p = 0.002). Values are expressed as the
tly different from each other. After a one-way ANOVA, Student–
increasing order from left to right: a > b > c (p < 0.05). C, control;
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http://www.lipidworld.com/content/11/1/147fed rats. Thus, the antioxidant activity of hepatic GPx
was higher in the HFOA group than in the HF group.
Indeed, a significant correlation (r = 0.986 and p =
0.002) has been established between a fall in MDA level
and an increase in GPx activity in response to the HFOA
diet. These results prove that O. aurita supplementation
of the HF diet reduces the hepatic oxidative stress after
7 weeks of treatments. Beside n-3 PUFA, O. aurita also
contains a large portion of pigments. Chlorophyll a and
fucoxanthin are the major pigments in O. aurita (30.0
and 20.4 % of total pigments, respectively). Many studies
have reported that micronutrients, such as polyphenols,
pigments, vitamins and minerals, can prevent or at least
attenuate the damage caused by oxidative stress. The
Feillet-Coudray et al. [56] study demonstrates that a
polyphenol extract seems to have some protective effects
against hepatic steatosis and against the oxidative stress
induced by high fat, high sucrose diet in rats. Fucoxan-
thin, like other carotenoids displays remarkable bioacti-
vities (antioxidant, anti-obesity etc.) that are relevant to
human health (for a review see Peng et al. [57]).
The present investigation showed that O. aurita could
be used as food supplement to prevent risk factors for
high-fat induced MS. The beneficial effects of O. aurita
showed in the present investigation could be due to a
synergistic effect between the various different active
microalgal components, such as n-3 PUFA and pig-
ments. Kay [58] proposed that the possible active ingre-
dients of Chlorella that reduce blood lipid levels could
be water-soluble fiber, vegetable protein, phospholipids,
Vitamin C, Vitamin E and beta-carotene. Furthermore
numerous authors have provided evidence that a com-
bination of phytosterols and n-3 fatty acids may reduce
cardiovascular risk in a complementary and synergistic
way [59,60].
In conclusion, our data show that O. aurita supple-
mentation reduces the risk factors for high-fat induced
MS in rats after 7 weeks of treatment. O. aurita intake
in HFOA-fed rats resulted in lower levels of glycemia,
triacylglycerols, and total cholesterol in plasma and liver
than the same levels found in HF-fed rats. Furthermore,
rats given the HFOA diet tended to have lower collagen-
induced platelet aggregation, decreased platelet TXB2
level and enhanced n-3 PUFA incorporation in plasma,
platelet, and liver lipids. Finally, O. aurita as food sup-
plement in HFOA-fed rats displayed an antioxidant ef-
fect in the liver, with lower levels of MDA and increased
GPx activity.
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